Developing drugs that do not cause tumor regression.
Stadler
Walter
W
University of Chicago, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D018450:Disease Progression; D004311:Double-Blind Method; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D047368:Tumor Burden; D014481:United States; D014486:United States Food and Drug Administration; D028761:Withholding Treatment
D000970:Antineoplastic Agents